Infections and Infectious Diseases | New Developments | FRANCE

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Sanofi joins forces with U.S. Department of Health for COVID-19

Lead Product(s): SARS vaccine

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Biomedical Advanced Research and Development Authority

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration February 18, 2020

Details:

Work with Biomedical Advanced Research and Development Authority (BARDA) will utilize Sanofi’s well-established recombinant technology platform to expedite a potential COVID-19 vaccine.

Eusa Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

EUSA Pharma and Papa Giovanni XXIII Hospital to Initiate an Observational Case-control Study of Siltuximab in COVID-19

Lead Product(s): Siltuximab

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 18, 2020

Details:

The step was followed by the release of initial data from China suggesting a role of IL-6 in the development of Acute Respiratory Distress Syndrome as a result of COVID-19.

Antabio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Antabio Awarded $4.4 Million From CARB-X for the Further Development of its New Treatment for Pseudomonas aeruginosa Infections in Cystic Fi...

Lead Product(s): Undisclosed

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: CARB-X

Deal Size: $4.4 million Upfront Cash: Undisclosed

Deal Type: Funding January 02, 2020

Details:

The funding is to support the development of Antabio's novel small molecule candidate for the treatment of Pseudomonas aeruginosa infections in Cystic Fibrosis (CF) patients.

Find

Find Novel Drugs for Infections and Infectious Diseases under Development in FRANCE

France

A collaboration with SCORR Marketing

Product Type

Companies

Sanofi

Sanofi joins forces with U.S. Department of Health for COVID-19

Eusa Pharma

EUSA Pharma and Papa Giovanni XXIII Hospital to Initiate an Observational Case-control Study of Siltuximab in COVID-19

Antabio

Antabio Awarded $4.4 Million From CARB-X for the Further Development of its New Treatment for Pseudomonas aeruginosa Infections in Cystic Fi...